LivaNova PLC (LIVN)vsNovartis AG ADR (NVS)
LIVN
LivaNova PLC
$72.36
-1.84%
HEALTHCARE · Cap: $4.36B
NVS
Novartis AG ADR
$148.38
-0.55%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3847% more annual revenue ($56.58B vs $1.43B). NVS leads profitability with a 23.9% profit margin vs 7.5%. LIVN appears more attractively valued with a PEG of 0.91. LIVN earns a higher WallStSmart Score of 52/100 (C-).
LIVN
Buy52
out of 100
Grade: C-
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.1%
Fair Value
$70.73
Current Price
$72.36
$1.63 discount
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
7.5% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.6%
Distress zone — elevated risk
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : LIVN
The strongest argument for LIVN centers on Debt/Equity, PEG Ratio. Revenue growth of 14.3% demonstrates continued momentum. PEG of 0.91 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : LIVN
The primary concerns for LIVN are Profit Margin, P/E Ratio, EPS Growth. A P/E of 40.5x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
LIVN profiles as a value stock while NVS is a declining play — different risk/reward profiles.
LIVN carries more volatility with a beta of 0.88 — expect wider price swings.
LIVN is growing revenue faster at 14.3% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
LIVN scores higher overall (52/100 vs 49/100) and 14.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?